Akt inhibition with MK-2206 is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, HER2 negative breast cancer [PI3K panel]

Gene expression was assessed with Nanostring in the surgical specimens obtained from a Window of Opportunity trial with MK-2206 in early stage breast cancer. Tumor biopsies and surgical specimens were compared for patients who received MK-2206 along with a prospective untreated control group of patients. Greater expression of interferon related genes was seen in surgical specimens following MK-2206 and compared to untreated controls. In the study/data presented here, patients with early stage breast cancer were treated with MK-2206 for two doses in a Window of Opportunity trial. Patients had corrollary studies performed on their pretreatment and post-treatment (surgical excision) specimens to assess the effect of MK-2206 on both known direct targets of the PI3KCA/Akt pathway as well as tumor immune microenvironment. Enclosed here is the nanostring data from the PI3K panel analysis of the surgical specimens from patients treated with MK-2206 as well as surgical specimens from an untreated prospective control cohort.